AAAAAA

   
Results: 1-12 |
Results: 12
Flow cytometric assay for the simultaneous analysis of cell-mediated cytotoxicity and effector cell phenotype
Authors: Derby, E Reddy, V Baseler, M Malyguine, A
Citation: E. Derby et al., Flow cytometric assay for the simultaneous analysis of cell-mediated cytotoxicity and effector cell phenotype, BIOTECHNIQU, 31(3), 2001, pp. 660
Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity
Authors: Derby, E Reddy, V Kopp, W Nelson, E Baseler, M Sayers, T Malyguine, A
Citation: E. Derby et al., Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity, IMMUNOL LET, 78(1), 2001, pp. 35-39
HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals
Authors: Moir, S Malaspina, A Ogwaro, KM Donoghue, ET Hallahan, CW Ehler, LA Liu, SY Adelsberger, J Lapointe, R Hwu, P Baseler, M Orenstein, JM Chun, TW Mican, JAM Fauci, AS
Citation: S. Moir et al., HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals, P NAS US, 98(18), 2001, pp. 10362-10367
Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
Authors: Kovacs, JA Vogel, S Metcalf, JA Baseler, M Stevens, R Adelsberger, J Lempicki, R Hengel, RL Sereti, I Lambert, L Dewar, RL Davey, RT Walker, RE Falloon, J Polis, MA Masur, H Lane, HC
Citation: Ja. Kovacs et al., Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy, EUR J IMMUN, 31(5), 2001, pp. 1351-1360
Longitudinal changes in CD4(+) T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients
Authors: Gea-Banacloche, JC Martino, L Mican, JM Hallahan, CW Baseler, M Stevens, R Lambert, L Polis, M Lane, HC Connors, M
Citation: Jc. Gea-banacloche et al., Longitudinal changes in CD4(+) T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients, AIDS RES H, 16(17), 2000, pp. 1877-1886
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
Authors: Kovacs, JA Imamichi, H Vogel, S Metcalf, JA Dewar, RL Baseler, M Stevens, R Adelsberger, J Lambert, L Davey, RT Walker, RE Falloon, J Polis, MA Masur, H Lane, HC
Citation: Ja. Kovacs et al., Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression, J INFEC DIS, 182(4), 2000, pp. 1063-1069
B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells
Authors: Moir, S Malaspina, A Li, YX Chun, TW Lowe, T Adelsberger, J Baseler, M Ehler, LA Liu, SY Davey, RT Mican, JAM Fauci, AS
Citation: S. Moir et al., B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells, J EXP MED, 192(5), 2000, pp. 637-645
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection
Authors: Walker, RE Bechtel, CM Natarajan, V Baseler, M Hege, KM Metcalf, JA Stevens, R Hazen, A Blaese, RM Chen, CC Leitman, SF Palensky, J Wittes, J Davey, RT Falloon, J Polis, MA Kovacs, JA Broad, DF Levine, BL Roberts, MR Masur, H Lane, HC
Citation: Re. Walker et al., Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection, BLOOD, 96(2), 2000, pp. 467-474
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
Authors: Davey, RT Bhat, N Yoder, C Chun, TW Metcalf, JA Dewar, R Natarajan, V Lempicki, RA Adelsberger, JW Millers, KD Kovacs, JA Polis, MA Walker, RE Falloon, L Masur, H Gee, D Baseler, M Dimitrov, DS Fauci, AS Lane, HC
Citation: Rt. Davey et al., HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression, P NAS US, 96(26), 1999, pp. 15109-15114
CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection:Potential role of B lymphocytes as a viral reservoir
Authors: Moir, S Lapointe, R Malaspina, A Ostrowski, M Cole, CE Chun, TW Adelsberger, J Baseler, M Hwu, P Fauci, AS
Citation: S. Moir et al., CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection:Potential role of B lymphocytes as a viral reservoir, J VIROLOGY, 73(10), 1999, pp. 7972-7980
Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages
Authors: Sleasman, JW Nelson, RP Goodenow, MM Wilfret, D Hutson, A Baseler, M Zuckerman, J Pizzo, PA Mueller, BU
Citation: Jw. Sleasman et al., Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages, J PEDIAT, 134(5), 1999, pp. 597-606
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
Authors: Davey, RT Chaitt, DG Albert, JM Piscitelli, SC Kovacs, JA Walker, RE Falloon, J Polis, MA Metcalf, JA Masur, H Dewar, R Baseler, M Fyfe, G Giedlin, MA Lane, HC
Citation: Rt. Davey et al., A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection, J INFEC DIS, 179(4), 1999, pp. 849-858
Risultati: 1-12 |